FDA Clearance Tracker · P170019-S045
FoundationOne CDx
Last checked: Nov 20, 2026Latest source record: Apr 25, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Apr 25, 2024
Approved
Time to decision
342 days
Received May 19, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P170019-S045
- Device name
- FoundationOne CDx
- Applicant
- Foundation Medicine, Inc.
- Applicant location
- Boston, MA
- Received
- May 19, 2023
- Decided
- Apr 25, 2024
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P170019
Device type
- Device type
- Next generation sequencing oncology panel, somatic or germline variant detection system (PQP)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
approval for the migration of the F1CDx from the HiSeq 4000 to NovaSeq 6000 configuration
Source documents
Other decisions for Foundation Medicine, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- FoundationOne CDx (F1CDx)PMA supplement
P170019-S060 · Decided May 27, 2026 · 614 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.